Ginsburg Geoffrey S, Konstance Richard P, Allsbrook Jennifer S, Schulman Kevin A
Department of Medicine, School of Medicine, Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA.
Arch Intern Med. 2005 Nov 14;165(20):2331-6. doi: 10.1001/archinte.165.20.2331.
Pharmacogenomics is likely to be among the first clinical applications of the Human Genome Project and is certain to have an enormous impact on the clinical practice of medicine. Herein, we discuss the potential implications of pharmacogenomics on the drug development process, including drug safety, productivity, market segmentation, market expansion, differentiation, and personalized health care. We also review 3 challenges facing the translation of pharmacogenomics into clinical practice: dependence on information technology, limited health care financing, and the scientific uncertainty surrounding validation of specific applications of the technology. To our knowledge, there is currently no formal agenda to promote and cultivate innovation, to develop progressive information technology, or to obtain the financing that would be required to advance the use of pharmacogenomic technologies in patient care. Although the potential of these technologies is driving change in the development of clinical sciences, it remains to be seen which health care systems level needs will be addressed.
药物基因组学很可能是人类基因组计划的首批临床应用领域之一,并且肯定会对医学临床实践产生巨大影响。在此,我们讨论药物基因组学对药物研发过程的潜在影响,包括药物安全性、生产效率、市场细分、市场拓展、差异化以及个性化医疗保健。我们还审视了将药物基因组学转化为临床实践所面临的三个挑战:对信息技术的依赖、医疗保健资金有限以及围绕该技术特定应用验证的科学不确定性。据我们所知,目前尚无正式议程来促进和培育创新、开发先进的信息技术,或获取推进药物基因组技术在患者护理中应用所需的资金。尽管这些技术的潜力正在推动临床科学发展的变革,但哪些医疗保健系统层面的需求将得到满足仍有待观察。